drugset
drugset / Trial / NCT01140425

Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects

NCT01140425 ↗

Phase 1 Completed 44 enrolled Pfizer ViiV Healthcare · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the affect that PF-00232798 has on QT interval. A prolonged QT interval is a risk factor for arrhythmias.

Timeline

Start
2010-07
Primary completion
2010-12
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject PF-00232798 Small molecule 300 mg Oral
Subject PF-00232798 Small molecule 600 mg Oral

Indications

No indication recorded.